Vertigo Clinical Trial
Official title:
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vertigo. The main question[s] it aims to answer are: - Which device do participants respond better to (that is, find more relief)? - To what degree do participants find relief? Participants will be: - Enrolled up to 49 days; 14 days in Baseline Phase (no device) and 21 days in Treatment Phase (study device) for Study Arm 1 or 28 days in Treatment Phase (study device) for Study Arm 2 - Randomized and stratified into groups based on diagnosis to be assigned a study device - Asked to use the study device as instructed by the study coordinator - Asked to download a study app to submit daily diaries regarding their symptoms and use of device, and to participate in tele-health visits with study coordinators - Asked to provide their vertigo diagnosis from their physician - Compensated for their participation Researchers will compare the randomized groups to see which groups respond better to which device.
This study is decentralized clinical trial. This study uses technology and and virtual meetings to communicate with study participants and collect study data. This study seeks to enroll until 36 participants in the MoW arm have completed the study, and until 72 participants have completed the QoL arm. All study participants that meet all of the inclusion, none of the exclusion criteria, and sign informed consent will be enrolled in the study. Participants will complete a one day enrollment meeting and an approximately 14 day Baseline Phase. After the Baseline Phase participants will be placed in one of two groups Moderate or Worse (MoW) group or Quality of Life (QoL) group based on the data collected about their vertigo during the Baseline Phase. Participants will then be randomized within their assigned group (MoW or QoL) at a 2:1 ratio to an active arm or sham arm to begin the Treatment Phase of the study. Participants will be sent a study device to use when they have a vertigo episode. Participants that enroll in the study are expected to participate up to 49 days with virtual meetings at the approximate intervals: MoW Group: Day 21, Day 24, Day 31, and Day 42 QoL Group : Day 16, Day, 24, Day 36, and Day 49 Participants will be required to complete the DHI (Dizziness Handicap Index), VSS (Vertigo Symptom Scale), Global Impression of Symptoms, and Global Impression of Change questionnaires. Otolith Labs received Therapeutic Breakthrough Device designation by the FDA in May, 2021 ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Recruiting |
NCT05533840 -
Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
|
||
Completed |
NCT02533739 -
Vestibular Disorder and Visuo-spatial Functions
|
N/A | |
Completed |
NCT01153789 -
Study of Oculomotor Dysfunction Leading to Children Vertigo
|
N/A | |
Completed |
NCT00765635 -
Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
|
Phase 4 | |
Not yet recruiting |
NCT04929444 -
Training to Improve Vertigo Management in Primary Care
|
N/A | |
Completed |
NCT04458376 -
Internet-based Self-help Program for Vestibular Rehabilitation in Chronic Dizziness
|
N/A | |
Not yet recruiting |
NCT04055766 -
A Diagnostic Test on DeepDoc-an AI-based Decision Support System
|
||
Recruiting |
NCT06332326 -
Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients
|
N/A | |
Completed |
NCT02938221 -
Telemedical Examination of a Three-Component Oculomotor Testing Battery
|
N/A | |
Active, not recruiting |
NCT02655575 -
Assessment and Treatment of Patients With Long-term Dizziness in Primary Care
|
N/A | |
Completed |
NCT02457455 -
Urgent Medical and Surgical Conditions During Flights
|
N/A | |
Enrolling by invitation |
NCT01426932 -
The Head Impulse Test in the Screening of Vestibular Function
|
N/A | |
Completed |
NCT00000359 -
Treatments for Benign Paroxysmal Positional Vertigo (BPPV)
|
Phase 2 | |
Not yet recruiting |
NCT06010550 -
Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo
|
||
Not yet recruiting |
NCT06017466 -
Translation and Implementation of the Dutch VVAS Score in Clinical Practice
|
N/A | |
Completed |
NCT04598113 -
Effect of Cervical Traction on Balance in Cervical Radiculopathy Patients
|
N/A | |
Completed |
NCT05157399 -
Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness
|
N/A | |
Completed |
NCT05897853 -
Impact of Vertigoheel® on Patients Suffering From Bilateral Vestibulopathy and Functional Dizziness
|
||
Completed |
NCT05221892 -
Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo
|
Phase 4 |